IMMUNOTHERAPY OF HUMAN NEOPLASMS WITH TRANSFER FACTOR

Abstract

This chapter discusses results of experiments conducted to study immunotherapy of human neoplasms with transfer factor (TF). The report describes team's experience with TF used as immunoadjuvant in the treatment of patients with malignant melanoma and renal cell carcinoma. It is stated that the initial study involved the use of dialyzable transfer factor prepared by the method of Lawrence, in six patients with metastatic melanoma. The experiments suggest that a significant change occurs in the levels of lymphocyte cytotoxicity against cultured renal carcinoma cells. Examination of the experimental data revealed that the use of transfer factor as an immunotherapeutic agent has several advantages including ease of administration, absence of serious side effects and increase in specific antitumor immunologic responses. The results suggest that transfer factor employed as an immunotherapeutic agent in patients with metastatic renal cell carcinoma and malignant melanoma has failed to produce objective tumor regression in nine instances.